(1S,4S)-4-phenyl-1,2,3,4-tetrahydronaphtalen-1-amine | 52371-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (1S,4S)-4-phenyl-1,2,3,4-tetrahydronaphtalen-1-amine
• 英文别名: (1S,4S)-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine
• CAS: 52371-26-3；52371-27-4；129459-27-4
• 化学式: C₁₆H₁₇N
• 分子量: 223.318
• InChiKey: IWNWWVPLTTUPBQ-BBRMVZONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX<br/>[FR] INHIBITEURS DE LA MYÉLOPEROXYDASE ET/OU DE L'EPX À BASE DE TRIAZOLOPYRIDINES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017161145A1

  公开（公告）日：2017-09-21

  The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

  本发明提供了式(I)的化合物；其中取代基各自如说明书中所定义，以及包含任一此类新颖化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，并且可用于治疗和/或预防动脉粥样硬化、心力衰竭、慢性阻塞性肺病（COPD）及相关疾病。
• [EN] PHARMACEUTICALLY ACCEPTABLE SALTS OF SERTRALINE AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] SELS PHARMACEUTIQUEMENT ACCEPTABLES DE SERTRALINE ET COMPOSITIONS PHARMACEUTIQUES CORRESPONDANTES
  申请人：PFIZER PROD INC

  公开号：WO2004065348A1

  公开（公告）日：2004-08-05

  The present invention is directed to certain pharmaceutically acceptable salts of the therapeutically potent selective serotonin reuptake inhibitor, sertraline: Formula (I), and pharmaceutical compositions thereof, wherein said salts are selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt and the (-)-camphor-10-sulfonic acid salt.

  本发明涉及治疗效果显著的选择性血清素再摄取抑制剂西替利嗪的某些药用可接受盐：化学式(I)，以及其制药组合物，其中所述盐选自对甲苯磺酸盐、富马酸盐、苯磺酸盐、苯甲酸盐、L-酒石酸盐和(-)-樟脑-10-磺酸盐的群组。
• PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150065505A1

  公开（公告）日：2015-03-05

  The present invention provides compounds of Formula (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了公式（I）所定义的化合物，以及包含任何此类新型化合物的组合物。这些化合物是内皮细胞脂肪酶抑制剂，可用作药物。
• Triazolopyridine inhibitors of myeloperoxidase and/or EPX
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11008317B2

  公开（公告）日：2021-05-18

  The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

  本发明提供了式(I)化合物；其中各取代基如说明书中所定义，以及包含任何此类新型化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用于治疗和/或预防动脉粥样硬化、心力衰竭、慢性阻塞性肺病（COPD）及相关疾病。
• Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
  申请人：Pfizer Inc

  公开号：US20040198818A1

  公开（公告）日：2004-10-07

  The present invention is directed to certain pharmaceutically acceptable salts of the therapeutically potent selective serotonin reuptake inhibitor, sertraline: 1 and pharmaceutical compositions thereof, wherein said salts are selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt and the (−)-camphor-10-sulfonic acid salt.

  本发明涉及具有治疗作用的选择性 5-羟色胺再摄取抑制剂舍曲林的某些药学上可接受的盐类： 1 及其药物组合物，其中所述盐类选自由对甲苯磺酸盐、富马酸盐、苯磺酸盐、苯甲酸盐、L-酒石酸盐和(-)-樟脑-10-磺酸盐组成的组。